Orphenadrine citrate (BioDeep_00000015217)

natural product

代谢物信息卡片

Orphenadrine citrate (Norflex)

化学式: C24H31NO8 (461.2049566)
中文名称: 枸橼酸奥芬那君, 枸櫞酸奧芬那君
谱图信息: 最多检出来源 Escherichia coli(natural_products) 33.33%

分子结构信息

SMILES: C1(C(OCCN(C)C)C2=CC=CC=C2C)(=CC=CC=C1).OC(CC(CC(O)=O)(C(=O)O)O)=O
InChI: 13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

描述信息

M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents > M03BC - Ethers, chemically close to antihistamines
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065686 - Cytochrome P-450 CYP2B6 Inhibitors
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents
C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant
Orphenadrine citrate is an orally active and non-competitive NMDA receptor antagonist (crosses the blood-brain barrier) with a Ki of 6.0 μM. Orphenadrine citrate relieves stiffness, pain and discomfort due to muscle strains, sprains or other injuries. Orphenadrine citrate is also used to relieve tremors associated with parkinson's disease. Orphenadrine citrate has good neuroprotective properties, can be used in studies of neurodegenerative diseases[1][2].

同义名列表

3 个代谢物同义名

Orphenadrine citrate; Orphenadrine citrate (Norflex); Orphenadrine (citrate)

数据库引用编号

10 个数据库交叉引用编号

ChEBI: CHEBI:7790
KEGG: C75247
KEGGdrug: D00774
PubChem: 83823
ChEMBL: CHEMBL1200395
MeSH: Orphenadrine
CAS: 4596-23-0
CAS: 4682-36-4
MoNA: CCMSLIB00000078409
medchemexpress: HY-B0369A

分类词条

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

文献列表

Anna Detzlhofer, Christian Grechhamer, Lawrence Madikizela, Markus Himmelsbach, Franz Mlynek, Wolfgang Buchberger, Christian W Klampfl. Uptake, translocation, and metabolization of amitriptyline, lidocaine, orphenadrine, and tramadol by cress and pea. Environmental science and pollution research international. 2024 Mar; 31(13):19649-19657. doi: 10.1007/s11356-024-32379-x. [PMID: 38363510]
Kit Yee Cheah, Kar Yee Mah, Lai Hui Pang, Shi Min Ng, Jia Woei Wong, Siew Siew Tan, Hong Zhe Tan, Kah Hay Yuen. A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition. BMC pharmacology & toxicology. 2020 06; 21(1):45. doi: 10.1186/s40360-020-00416-3. [PMID: 32576287]
Jessica L Knittel, Shawn P Vorce, Barry Levine, Rhome L Hughes, Thomas Z Bosy. Multidrug toxicity involving sumatriptan. Journal of analytical toxicology. 2015 Jan; 39(1):75-9. doi: 10.1093/jat/bku120. [PMID: 25324526]
Iu I Hubs'kyĭ, T A Bukhtiarova, H H Horiushko, N V Litvinova, H I Paramonova, T M Kurapova, O M Velychko, L P Babenko. [Biophysical parameters of erythrocyte membranes and mechanisms of interaction with non-opioid analgesics under acute pain syndrome]. Ukrainian biochemical journal. 2014 May; 86(3):98-106. doi: ". [PMID: 25033559]
M A Saracino, C Petio, M Vitali, L Franchini, M A Raggi. Determination of orphenadrine plasma levels using HPLC with diode array detection and a novel solid-phase extraction procedure in psychiatric patients. Journal of pharmaceutical and biomedical analysis. 2009 Oct; 50(3):501-6. doi: 10.1016/j.jpba.2009.05.010. [PMID: 19524386]
Mirosław Czuczwar, Jacek Cieszczyk, Katarzyna Czuczwar, Jacek Kiś, Tomasz Saran, Waldemar A Turski. Influence of orphenadrine upon the protective activity of various antiepileptics in the maximal electroshock-induced convulsions in mice. Pharmacological reports : PR. 2009 Jul; 61(4):732-6. doi: 10.1016/s1734-1140(09)70127-6. [PMID: 19815957]
M Elghazali, I A Wasfi, A A Abdel Hadi, A M Latum. Pharmacokinetic, metabolism and withdrawal time of orphenadrine in camels (Camelus dromedarius) after intravenous administration. Research in veterinary science. 2008 Dec; 85(3):563-9. doi: 10.1016/j.rvsc.2008.01.006. [PMID: 18321539]
María Amparo Martínez-Gómez, Rosa M Villanueva-Camañas, Salvador Sagrado, María José Medina-Hernández. Evaluation of enantioselective binding of antihistamines to human serum albumin by ACE. Electrophoresis. 2007 Aug; 28(15):2635-43. doi: 10.1002/elps.200600742. [PMID: 17605150]
Mei-juan Xu, Guang-ji Wang, Hai-tang Xie, Qing Huang, Yuan-wei Jia. [Enzyme kinetics of schizandrin metabolism and sex differences in rat liver microsomes]. Yao xue xue bao = Acta pharmaceutica Sinica. 2007 Jul; 42(7):730-4. doi: . [PMID: 17882956]
Soo-Youn Lee, Hyeon Ju Oh, Jong Won Kim, Yoon Gyoon Kim, Chul Jin Moon, Eun Hee Lee. Pharmacokinetic study of orphenadrine using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Jul; 839(1-2):118-23. doi: 10.1016/j.jchromb.2006.02.056. [PMID: 16580894]
N Fucci, B Romano, A Zirilli. Acute intoxication with orphenadrine and clozapine. Forensic science international. 2001 Nov; 123(1):13-6. doi: 10.1016/s0379-0738(01)00509-6. [PMID: 11731191]
I Van Herreweghe, K Mertens, V Maes, J Ramet. Orphenadrine poisoning in a child: clinical and analytical data. Intensive care medicine. 1999 Oct; 25(10):1134-6. doi: 10.1007/s001340051024. [PMID: 10551971]
E G Brain, L J Yu, K Gustafsson, P Drewes, D J Waxman. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. British journal of cancer. 1998 Jun; 77(11):1768-76. doi: 10.1038/bjc.1998.295. [PMID: 9667645]
D Hannak, F Scharbert, R Kattermann. Stepwise binary gradient high-performance liquid chromatographic system for routine drug monitoring. Journal of chromatography. A. 1996 Mar; 728(1-2):307-10. doi: 10.1016/0021-9673(95)01169-2. [PMID: 8673233]
M Contin, R Riva, P Martinelli, G Procaccianti, F Albani, A Baruzzi. Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. Effect on levodopa bioavailability. Clinical neuropharmacology. 1991 Apr; 14(2):148-55. doi: 10.1097/00002826-199104000-00004. [PMID: 2015611]
A C Altamura, M C Mauri, F De Novellis, M Percudani, V Vampini. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine. Pharmacopsychiatry. 1989 Nov; 22(6):246-9. doi: 10.1055/s-2007-1014608. [PMID: 2616635]
J M Treherne, J M Young. [3H]-(+)-N-methyl-4-methyldiphenhydramine, a quaternary radioligand for the histamine H1-receptor. British journal of pharmacology. 1988 Jul; 94(3):797-810. doi: 10.1111/j.1476-5381.1988.tb11591.x. [PMID: 3179613]
M Contin, R Riva, F Albani, A Baruzzi. Simple and rapid GLC method for the determination of orphenadrine in human plasma. Biomedical chromatography : BMC. 1987; 2(5):193-4. doi: 10.1002/bmc.1130020504. [PMID: 3507235]
G T Blyden, D J Greenblatt, J M Scavone, R I Shader. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. Journal of clinical pharmacology. 1986 Sep; 26(7):529-33. doi: 10.1002/j.1552-4604.1986.tb02946.x. [PMID: 3760245]
A C Altamura, M Buccio, F Colacurcio, G Colombo, A Terzi. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol. Acta neurologica. 1986 Feb; 8(1):19-26. doi: NULL. [PMID: 3962752]
A C Altamura, M Buccio, G Colombo, A Terzi, C L Cazzullo. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study. L'Encephale. 1986 Jan; 12(1):31-6. doi: . [PMID: 3698889]
M Furlanut, D Bettio, I Bertin, G Colombo, P Benetello. Orphenadrine serum levels in a poisoned patient. Human toxicology. 1985 May; 4(3):331-3. doi: 10.1177/096032718500400316. [PMID: 4007897]
A Bast, E M Savenije-Chapel, J Noordhoek. Relationship between molecular structure and cytochrome P450-metabolic intermediate complex formation, studied with orphenadrine analogues. Journal of pharmaceutical sciences. 1984 Jul; 73(7):953-6. doi: 10.1002/jps.2600730723. [PMID: 6470960]
R C Meatherall, D R Guay. Isothermal gas chromatographic analysis of diphenhydramine after direct injection onto a fused-silica capillary column. Journal of chromatography. 1984 May; 307(2):295-304. doi: 10.1016/s0378-4347(00)84101-8. [PMID: 6736178]
D Lutz, W Gielsdorf, H Jaeger. Quantitative determination of diphenhydramine and orphenadrine in human serum by capillary gas chromatography. Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie. 1983 Oct; 21(10):595-7. doi: 10.1515/cclm.1983.21.10.595. [PMID: 6644246]
L F Wilkinson, B M Thomson, L K Pannell. A report on the analysis of orphenadrine in post mortem specimens. Journal of analytical toxicology. 1983 Mar; 7(2):72-5. doi: 10.1093/jat/7.2.72. [PMID: 6855206]
L I Harrison, C R Kehe, M B Goldlust, D C Kvam, J R Bianchine. Salicylic acid plasma levels following multiple doses of Norgesic Forte and aspirin. Therapeutic drug monitoring. 1983; 5(4):401-4. doi: 10.1097/00007691-198312000-00004. [PMID: 6689225]
G Rutigliano, J J Labout. The bioavailability of orphenadrine hydrochloride after intramuscular and oral administration. The Journal of international medical research. 1982; 10(6):447-50. doi: 10.1177/030006058201000612. [PMID: 7152086]
J J Labout, C t Thijssen, G G Keijser, W Hespe. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. European journal of clinical pharmacology. 1982; 21(4):343-50. doi: 10.1007/bf00637624. [PMID: 7056281]
G B Burnett, A J Prange, I C Wilson, L A Jolliff, I C Creese, S H Synder. Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism. Neuropsychobiology. 1980; 6(2):109-20. doi: 10.1159/000117742. [PMID: 6101910]
J Huisman, L L Liebregt, J H Thyssen. Gas chromatographic determination of (o-methyl-alpha-phenylbenzyloxy)acetic acid levels in human serum following therapeutic doses of orphenadrin (Disipal). Journal of chromatography. 1979 Dec; 164(4):510-4. doi: 10.1016/s0378-4347(00)81555-8. [PMID: 541428]
L B Hansen, J Elley, T R Christensen, N E Larsen, J Naestoft, E F Hvidberg. Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. British journal of clinical pharmacology. 1979 Jan; 7(1):75-80. doi: 10.1111/j.1365-2125.1979.tb00900.x. [PMID: 760745]
P M Cotes, T J Crow, E C Johnstone, W Bartlett, R C Bourne. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication. Psychological medicine. 1978 Nov; 8(4):657-65. doi: 10.1017/s0033291700018869. [PMID: 364517]
J J Labout, C T Thijssen, W Hespe. Sensitive and specific gas chromatographic and extraction method for the determination of orphenadrine in human body fluids. Journal of chromatography. 1977 Dec; 144(2):201-8. doi: 10.1016/s0021-9673(00)99355-5. [PMID: 925110]
W M Wiersinga, A J Fabius, J L Touber. Orphenadrine (Disipal), serum thyroxine and thyroid function. Acta endocrinologica. 1977 Nov; 86(3):522-32. doi: 10.1530/acta.0.0860522. [PMID: 72472]
A E Robinson, A T Holder, R D McDowall, R Powell, H Sattar. Forensic toxicology of some orphenadrine-related deaths. Forensic science. 1977 Jan; 9(1):53-62. doi: 10.1016/0300-9432(77)90067-x. [PMID: 838418]
G Mendelson. Letter: Hallucinogenic plants. The Medical journal of Australia. 1975 Jun; 1(26):839. doi: ". [PMID: 1152781]
S Loga, S Curry, M Lader. Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. British journal of clinical pharmacology. 1975 Jun; 2(3):197-208. doi: 10.1111/j.1365-2125.1975.tb01576.x. [PMID: 791320]
J U Postma, W Van Tilburg. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). Journal of the American Geriatrics Society. 1975 May; 23(5):212-5. doi: 10.1111/j.1532-5415.1975.tb00187.x. [PMID: 123540]
D G Gill, H A Sowerby. Orphenadrine poisoning in childhood. The Practitioner. 1975 Apr; 214(1282):542-544. doi: NULL. [PMID: 1144265]
M H Lader. [Rational utilization of the major tranquilizers]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952). 1975; 75(9):1401-5. doi: NULL. [PMID: 241182]
D A Bender, A N Bamji. Serum tryptophan binding in chlorpromazine-treated chronic schizophrenics. Journal of neurochemistry. 1974 May; 22(5):805-9. doi: 10.1111/j.1471-4159.1974.tb04298.x. [PMID: 4407100]
P R Andersen, P Gibbs, H Kubinski. Effects of neuropharmacological agents on in vitro formation of complexes between nucleic acids and proteins. Neuropharmacology. 1974 Feb; 13(2):111-7. doi: 10.1016/0028-3908(74)90028-8. [PMID: 4595677]
W Bilzer, U Gundert-Remy. Determination of nanogram quantities of diphenhydramine and orphenadrine in human plasma using gas-liquid chromatography. European journal of clinical pharmacology. 1973 Dec; 6(4):268-70. doi: 10.1007/bf00644744. [PMID: 4777260]
T Ellison. Metabolic studies of 3 H-orphenadrine citrate in the rat, dog and rhesus monkey. Archives internationales de pharmacodynamie et de therapie. 1972 Feb; 195(2):213-30. doi: NULL. [PMID: 4622666]
A H Beckett, F Khan. Metabolism, distribution and excretion of orphenadrine in man. The Journal of pharmacy and pharmacology. 1971 Dec; 23(?):222S. doi: 10.1111/j.2042-7158.1971.tb08802.x. [PMID: 4401471]
T Ellison, A Snyder, J Bolger, R Okun. Metabolism of orphenadrine citrate in man. The Journal of pharmacology and experimental therapeutics. 1971 Feb; 176(2):284-95. doi: NULL. [PMID: 5568779]
H Prins, W Hespe. Autoradiographic study of the distribution of radioactivity in mice after oral administration of tritium-labelled orphenadrine hydrochloride. Archives internationales de pharmacodynamie et de therapie. 1968 Jan; 171(1):47-57. doi: NULL. [PMID: 5646024]
W Hespe, W F Kafoe, W T Nauta. Evidence for side-chain degradation of orphenadrine HCl in the rat. Biochemical pharmacology. 1967 Sep; 16(9):1847-8. doi: 10.1016/0006-2952(67)90262-6. [PMID: 6053225]
L R Gjessing. Effect of thyroxine, pyridoxine, orphenadrine-HCl, resperine and disulfiram in periodic catatonia. Acta psychiatrica Scandinavica. 1967; 43(4):376-84. doi: 10.1111/j.1600-0447.1967.tb05775.x. [PMID: 5582389]
J Johnson, G Milner. Psychiatric complications of amphetamine substances. Acta psychiatrica Scandinavica. 1966; 42(3):252-63. doi: 10.1111/j.1600-0447.1966.tb01930.x. [PMID: 5959089]
A HERZ, H TESCHEMACHER, A HOFSTETTER, H KURZ. THE IMPORTANCE OF LIPID-SOLUBILITY FOR THE CENTRAL ACTION OF CHOLINOLYTIC DRUGS. International journal of neuropharmacology. 1965 Jul; 4(?):207-18. doi: 10.1016/0028-3908(65)90037-7. [PMID: 14343875]
W Hespe, A M de Roos, W T Nauta. Investigation into the metabolic fate of orphenadrine hydrochloride after oral administration to male rats. Archives internationales de pharmacodynamie et de therapie. 1965 Jul; 156(1):180-200. doi: NULL. [PMID: 5858833]
VAN DEENENL, R A DEMEL. PENETRATION OF LIPID MONOLAYERS BY PSYCHOACTIVE DRUGS. Biochimica et biophysica acta. 1965 Jan; 94(?):314-6. doi: 10.1016/0926-6585(65)90039-7. [PMID: 14273414]